<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175367</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-CL-1643</org_study_id>
    <secondary_id>2017-001508-31</secondary_id>
    <nct_id>NCT03175367</nct_id>
  </id_info>
  <brief_title>Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in
      comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or
      non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite
      receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70
      mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L)
      for those patients without clinical ASCVD.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Anticipated">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">May 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in calculated low-density lipoprotein cholesterol (LDL-C) from baseline to week 16 in the intent-to-treat (ITT) population.</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apolipoprotein B (ApoB) from baseline to week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in non high-density lipoprotein cholesterol (HDL-C) from baseline to week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total cholesterol (TC) from baseline to week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥ 30% reduction in calculated LDL-C at week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥ 50% reduction in calculated LDL-C at week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in triglycerides (TGs) from baseline to week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Lipoprotein(a) [(Lp(a)] from baseline to week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with calculated LDL-C &lt; 100 mg/dL (2.59 mmol/L) at week 16</measure>
    <time_frame>Baseline and at Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with calculated LDL-C &lt; 70 mg/dL (1.81 mmol/L) at week 16</measure>
    <time_frame>Baseline and at Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with calculated LDL-C &lt; 50 mg/dL (1.81 mmol/L) at week 16</measure>
    <time_frame>Baseline and at Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in calculated LDL-C from baseline to week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>(only applicable to those participants receiving IV route of study treatment administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in calculated ApoB from baseline to week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>(only applicable to those participants receiving IV route of study treatment administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in calculated non-HDL-C from baseline to week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>(only applicable to those participants receiving IV route of study treatment administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in calculated TC from baseline to week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>(only applicable to those participants receiving IV route of study treatment administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in calculated TG from baseline to week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>(only applicable to those participants receiving IV route of study treatment administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in calculated Lp(a) from baseline to week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>(only applicable to those participants receiving IV route of study treatment administration)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Group A: dosing regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC Evinacumab QW for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A: dosing regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A: dosing regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC Evinacumab QW for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A: matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo SC QW for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: dosing regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) Evinacumab Q4W for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: dosing regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Evinacumab Q4W for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo IV Q4W for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evinacumab</intervention_name>
    <description>SC or IV administration</description>
    <arm_group_label>Group A: dosing regimen 1</arm_group_label>
    <arm_group_label>Group A: dosing regimen 2</arm_group_label>
    <arm_group_label>Group A: dosing regimen 3</arm_group_label>
    <arm_group_label>Group B: dosing regimen 1</arm_group_label>
    <arm_group_label>Group B: dosing regimen 2</arm_group_label>
    <other_name>REGN1500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>SC or IV administration</description>
    <arm_group_label>Group A: matching placebo</arm_group_label>
    <arm_group_label>Group B: matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Background Lipid Modifying Therapy (LMT)</intervention_name>
    <description>All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.</description>
    <arm_group_label>Group A: dosing regimen 1</arm_group_label>
    <arm_group_label>Group A: dosing regimen 2</arm_group_label>
    <arm_group_label>Group A: dosing regimen 3</arm_group_label>
    <arm_group_label>Group A: matching placebo</arm_group_label>
    <arm_group_label>Group B: dosing regimen 1</arm_group_label>
    <arm_group_label>Group B: dosing regimen 2</arm_group_label>
    <arm_group_label>Group B: matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The inclusion/ exclusion criteria below, include, but are not limited to, the following:

        Key Inclusion Criteria:

          1. Men and women, ages 18 through 80 at the screening visit

          2. Diagnosis of primary hypercholesterolemia, either HeFH or non-HeFH with clinical ASCVD

          3. A history of clinical ASCVD, for those patients who are non-HeFH.

          4. Receiving a stable maximally tolerated statin (± ezetimibe) for at least 4 weeks at
             screening

          5. For those patients with HeFH who are not receiving a statin at screening,
             documentation of inability to tolerate at least 2 statins.

          6. Receiving alirocumab 150 mg SC Q2W, OR evolocumab 140 mg SC Q2W or 420 mg SC Q4W for
             at least 8 weeks prior to the screening visit

          7. For those patients with a history of clinical ASCVD, serum LDL-C ≥ 70 mg/dL at
             screening (1 repeat lab is allowed)

          8. For those patients without a history of clinical ASCVD, serum LDL-C ≥ 100 mg/dL at
             screening (1 repeat lab is allowed)

          9. Provide signed informed consent

        Key Exclusion Criteria:

          1. Known history of homozygous FH (clinically, or by previous genotyping)

          2. Presence of any clinically significant uncontrolled endocrine disease known to
             influence serum lipids or lipoproteins

          3. Newly diagnosed diabetes (within 3 months prior to screening)

          4. Use of thyroid medications (except for replacement therapy which has been stable for
             at least 12 weeks before screening)

          5. Laboratory findings during screening period (not including randomization labs):

               1. Triglycerides &gt; 400 mg/dL (&gt; 4.52 mmol/L) for patients without a known history of
                  diabetes mellitus; OR Triglycerides &gt; 300 mg/dL (&gt; 3.39 mmol/L) for patients with
                  a known history of diabetes mellitus

               2. Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody
                  (associated with a positive HCV ribonucleic acid [RNA] polymerase chain reaction)

               3. Positive serum beta-human chorionic gonadotropin or urine pregnancy test in women
                  of childbearing potential

               4. Estimated glomerular filtration rate &lt; 30 mL/min/1.73 m^2

               5. TSH &gt; 1.5 x ULN

               6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 x ULN

          6. Systolic blood pressure &gt; 160 mmHg or diastolic blood pressure &gt; 100 mmHg at screening
             visit or time of randomization

          7. History of heart failure (New York Heart Association [NYHA] Class III-IV) within 12
             months before screening

          8. History of MI, unstable angina leading to hospitalization, CABG surgery, PCI,
             uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, TIA, carotid
             revascularization, endovascular procedure or surgical intervention for peripheral
             vascular disease within 3 months prior screening

          9. History of cancer within the past 5 years (except for adequately treated basal cell
             skin cancer, squamous cell skin cancer, or in situ cervical cancer)

         10. Having received LDL apheresis within 2 months before screening

         11. Pregnant or breast-feeding women

         12. Women of childbearing potential who are unwilling to practice a highly effective birth
             control method

         13. Men who are sexually active with women of childbearing potential (WOCBP) and are
             unwilling to consistently use condoms during the study drug treatment period
             regardless of vasectomy status.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. John D Homan MD</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663-3668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preventive Cardiology Inc</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Research Center Inc</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Lipid Institute</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Medical Group, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMMC Northeast Cardiology Assocites</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Health Cardiology</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt Sinai Ichan Medical Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowan Diagnostic Clinic</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Area Research, LLC</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas Health Science Center Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Premiere Internal Medicine</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clear Clinical Research, LLC</name>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <zip>78154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaTex Research</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redcliffe Hospital</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>1020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Innsbruck - Tyrolean Hospital</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Etudes Cliniques Econogene-21</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des maladies lipidiques de Quebec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Prague, S.R.O</name>
      <address>
        <city>Praha</city>
        <state>Prague 3</state>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzita Karlova v Praze 1 Lekarska Fakulta</name>
      <address>
        <city>Karlov</city>
        <state>Praha 2</state>
        <zip>121 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Charles University</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50008</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikem Institut Klinicke A Experimentalni Mediciny</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Herning</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital G Et R Laennec</name>
      <address>
        <city>Nantes</city>
        <state>Cedex</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houpital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>H̱olon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Mc</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center, Cardiovascular Research Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Federico II di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele Monasterio Per La Ricerca Medica E Di Sanita Pubblica</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Della Romagna-Ospedale Degli Infermi</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Traslazionale e di Precisione dell'Università degli Studi di</name>
      <address>
        <city>Rome</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Fujisawa Tokushukai Hospital</name>
      <address>
        <city>Fujisawa-shi</city>
        <zip>251-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minamino Cardiovascular Hospital</name>
      <address>
        <city>Hachioji</city>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital</name>
      <address>
        <city>Iruma-gun</city>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istishari Hospital</name>
      <address>
        <city>Amman</city>
        <zip>11184</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdullah University Hospital-1</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdullah University Hospital-2</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdullah University Hospital</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VOC Hoorn</name>
      <address>
        <city>Hoorn</city>
        <state>Hoorn Noord-Hollan</state>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter Ziekenhuis</name>
      <address>
        <city>Goes</city>
        <state>Zeeland</state>
        <zip>4462 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrech - Locatie AZU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid and Diabetes Research Group</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papamoa Pines Medical Centre</name>
      <address>
        <city>Papamoa</city>
        <zip>3118</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Horizons NZ Ltd</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Helse AS</name>
      <address>
        <city>Oslo</city>
        <zip>0373</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halina Serafin NZOZ Centrum Medyczne SERAFIN-MED</name>
      <address>
        <city>Żarów</city>
        <state>Dolnoslaskie</state>
        <zip>58-130</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Przychodnia Specjalistyczna</name>
      <address>
        <city>Ruda Slaska</city>
        <state>Podlaskie</state>
        <zip>41709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slaskie Centrum Chorob Serca, III Katedra i Oddzial Kliniczny Kardiologii SUM- Oddzial Chorob Serca i Naczyn</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovacsular Disease</name>
      <address>
        <city>Kemerovo</city>
        <zip>65000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Center For Preventative Medicine of Federal Agency of High Technology Medical Aid</name>
      <address>
        <city>Moscow</city>
        <zip>119990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution Out-patient Clinic 3</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NII of Therapy and Preventive Medicine</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Medical and Prophylactic Institution - City Hospital for Emergency Care No.2</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>34406</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limmited Liability Company International Medical Centre SOGAZ</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution of Healthcare Clinical Hospital #122 N.A.L.G Sokolov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC- Institute of Medical Research</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution Clinical-Diagnostic Center with Polyclinic</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Regional Clinical Cardiologic Dispensary</name>
      <address>
        <city>Samara</city>
        <zip>443070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Research Institute</name>
      <address>
        <city>Tomsk</city>
        <zip>34012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Charlotte Maxeke Johannesburg Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jongaie Research</name>
      <address>
        <city>Pretoria</city>
        <state>West Gauteng</state>
        <zip>182</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr JM Engelbrecht Trial Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>713</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TREAD Research CC</name>
      <address>
        <city>Parow</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruna</name>
      <address>
        <city>A Coruña</city>
        <state>A Coruna</state>
        <zip>15001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragon</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves (HUVN)</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akardo MedSite</name>
      <address>
        <city>Stockholm</city>
        <zip>11446</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital-Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary - The Newcastle Upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Jordan</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

